These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37603592)

  • 1. Guanidinylated Amphiphilic Tobramycin Derivatives Synergize with β-Lactam/β-Lactamase Inhibitor Combinations against
    Ramirez DM; Ramirez D; Dhiman S; Arora R; Lozeau C; Arthur G; Zhanel G; Schweizer F
    ACS Infect Dis; 2023 Sep; 9(9):1754-1768. PubMed ID: 37603592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant
    Dhiman S; Ramirez D; Li Y; Kumar A; Arthur G; Schweizer F
    ACS Infect Dis; 2023 Apr; 9(4):864-885. PubMed ID: 36917096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
    Idowu T; Ammeter D; Arthur G; Zhanel GG; Schweizer F
    J Antimicrob Chemother; 2019 Sep; 74(9):2640-2648. PubMed ID: 31139830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
    Haines RR; Putsathit P; Hammer KA; Tai AS
    Sci Rep; 2022 Oct; 12(1):16814. PubMed ID: 36207358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 9. Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against
    Dhiman S; Ramirez D; Arora R; Gandhi K; Wimalasekara R; Arthur G; Kumar A; Schweizer F
    ACS Omega; 2023 Aug; 8(32):29359-29373. PubMed ID: 37599980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity of ceftazidime, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.
    Rolston KV; Chandrasekar PH; LeFrock JL; Schell RF
    Chemotherapy; 1984; 30(1):31-4. PubMed ID: 6420119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Scribner RK; Marks MI; Weber AH; Tarpay MM; Welch DF
    Antimicrob Agents Chemother; 1982 Jun; 21(6):939-43. PubMed ID: 6810757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
    Idowu T; Ammeter D; Brizuela M; Jackson G; Alam S; Schweizer F
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127575. PubMed ID: 32980511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
    [No Abstract]   [Full Text] [Related]  

  • 16. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.
    Montaner M; Lopez-Argüello S; Oliver A; Moya B
    Microbiol Spectr; 2023 Feb; 11(1):e0303822. PubMed ID: 36475840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Lomovskaya O; Rubio-Aparicio D; Nelson K; Sun D; Tsivkovski R; Castanheira M; Lindley J; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility.
    Ferrer-Espada R; Sánchez-Gómez S; Pitts B; Stewart PS; Martínez-de-Tejada G
    Int J Antimicrob Agents; 2020 Jul; 56(1):105986. PubMed ID: 32335279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.